Hepatocellular Carcinoma in HIV-Infected Patients: Check Early, Treat Hard

Berretta, Massimiliano; Garlassi, Elisa; Cacopardo, Bruno; Cappellani, Alessandro; Guaraldi, Giovanni; Cocchi, Stefania; Paoli, Paolo De; Lleshi, Arben; Izzi, Immacolata; Torresin, A.; Gangi, P. Di; Pietrangelo, Antonello; Ferrari, Mariachiara; Bearz, Alessandra; Berretta, Salvatore; Nasti, Guglielmo; Benedetto, Fabrizio Di; Balestreri, Luca; Tirelli, Umberto; Ventura, Paolo

doi:10.1634/theoncologist.2010-0400

Cited by 92 publications

(104 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This clinical condition is a leading cause of non-AIDS solid cancers and a major cause of death in HIV-infected patients [3].…”

Section: Discussionmentioning

confidence: 99%

“…Several reports have outlined a more aggressive course of HCC in HIVinfected patients. HIV, per se, can boost carcinogenesis with the pivotal role of the HIV-tat protein inducing growth signals and enhancing HCC cell proliferation and antitumor immune response [3][4][5][6][7][8]. Furthermore, the increased life expectancy of HIV-infected patients, secondary to availability of highly active antiretroviral therapy (HAART) may allow the evolution of underlying liver diseases toward HCC and an increased [2, 9 -11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multicenter Italian Experience in Liver Transplantation for Hepatocellular Carcinoma in HIV-Infected Patients

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…This clinical condition is a leading cause of non-AIDS solid cancers and a major cause of death in HIV-infected patients [3].…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Multicenter Italian Experience in Liver Transplantation for Hepatocellular Carcinoma in HIV-Infected Patients

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Lastly, aflatoxin B1 exposure, tobacco use, coffee consumption, use of oral contraceptives and betel quid are other proven risk factors of HCC (2,5). Of note, HIV-positive patients with HCC had a significantly shorter survival time than HIV-negative counterparts (8).…”

mentioning

confidence: 99%

The Evolving Role of Local Treatments for HCC in the Third Millennium

Magistri

Tarantino

Ballarin

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…The survival was poorer in the HIVpositive patients even though in these patients HCC was more frequently diagnosed at an early stage. However the subgroup of HIVpositive patients receiving HAART and with an undetectable HIV viral load had a better outcome than patients with an higher plasmatic HIV RNA [51] . In this study, even thought the treatment rates were similar between HIV positive and HIVnegative patients, the overall survival rate was worse in the HIVpositive group, maybe due the fact that in these patients retreatment of an HCC recurrence was considered in a lower number of cases.…”

Section: Hepatocellular Carcinomamentioning

confidence: 87%

Non-AIDS definings malignancies among human immunodeficiency virus-positive subjects: Epidemiology and outcome after two decades of HAART era

Brugnaro¹,

Morelli²,

Cattelan³

et al. 2015

WJV

View full text Add to dashboard Cite

Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection has been widely available in industrialized countries since 1996; its widespread use determined a dramatic decline in acquired immunodeficiency syndrome (AIDS)-related mortality, and consequently, a significant decrease of AIDS-defining cancers. However the increased mean age of HIVinfected patients, prolonged exposure to environmental and lifestyle cancer risk factors, and coinfection with oncogenic viruses contributed to the emergence of other malignancies that are considered non-AIDS-defining cancers (NADCs) as a relevant fraction of morbidity and mortality among HIV-infected people twenty years after HAART introduction. The role of immunosuppression in the pathogenesis of NADCs is not well defined, and future researches should investigate the etiology of NADCs. In the last years there is a growing evidence that intensive chemotherapy regimens and radiotherapy could be safely administrated to HIV-positive patients while continuing HAART. This requires a multidisciplinary approach and a close co-operation of oncologists and HIV-physicians in order to best manage compliance of patients to treatment and to face drug-related side effects. Here we review the main epidemiological features, risk factors and clinical behavior of the more common NADCs, such as lung cancer, hepatocellular carcinoma, colorectal cancer and anal cancer, Hodgkin's lymphoma and some cutaneous malignancies, focusing also on the current therapeutic approaches and preventive screening strategies.

show abstract

Hepatocellular Carcinoma in HIV-Infected Patients: Check Early, Treat Hard

Abstract: Purpose. Hepatocellular carcinoma (HCC) is an increasing cause of mortality in HIV-infected patients in the highly active antiretroviral therapy (HAART) era.

Cited by 92 publications

References 41 publications

Multicenter Italian Experience in Liver Transplantation for Hepatocellular Carcinoma in HIV-Infected Patients

Multicenter Italian Experience in Liver Transplantation for Hepatocellular Carcinoma in HIV-Infected Patients

The Evolving Role of Local Treatments for HCC in the Third Millennium

Non-AIDS definings malignancies among human immunodeficiency virus-positive subjects: Epidemiology and outcome after two decades of HAART era

Contact Info

Product

Resources

About